Australian Psychedelics: Incannex Business & Financials, New Research Center For Mushrooms & Eating Disorders
Clinical-stage biopharma company Incannex Healthcare Ltd. (NASDAQ: IXHL) shared its quarterly activities report and appendix 4C for the period ended 30 September 2022, noticeably applying for several U.S.